Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.

Biotechnology

Education

Verve Therapeutics

Shanelle is a senior research associate, next generation sequencing at Verve Therapeutics. Prior to joining Verve, Shanelle worked at the Broad Institute, preparing samples for sequencing projects ranging from basic QC of sample quality to diagnostic testing for rare genetic conditions. Shanelle received her B.S.E in chemical engineering, focusing on biological engineering, from University of Massachusetts Lowell.

Shanelle Samuels

Bharathi is an analyst II, quality control at Verve Therapeutics. Prior to joining Verve, Bharathi worked as a process development associate at the Broad Institute, genomics platform, in COVID-19 diagnostics and genomic sequencing operations. While there, she developed and validated NGS technology for a stealth mode sequencing startup. She has a B.S. degree in nutritional sciences from University of California, Davis and M.S. degrees in public health nutrition and biomedical sciences from Boston University.

Bharathi Gandi

Pratik is the director, process development at Verve Therapeutics. Prior to joining Verve, Pratik was an associate director at Editas Medicine, where he led the team responsible for the development and scale-up of gene editing components to support both ex-vivo and in-vivo applications. Additionally, Pratik served as a CMC team lead at Editas, where he helped develop the overall strategy, timelines, and budgets necessary to establish an mRNA-LNP platform process to enable upcoming programs using CRISPR-based gene editing. Prior to joining Editas, Pratik worked at Pfizer as a senior scientist where he focused on formulation and process development of complex generics and biologics. Pratik received his Ph.D. from Northwestern University, in biomedical engineering, with an emphasis on surface chemistry, the development of nano-drug delivery systems, and biotechnology.

Pratik Randeria

Brittney is a scientist II, biophysical characterization at Verve Therapeutics. She received her degree from the University of Washington and worked at various companies, on the west coast ,focusing on analytical development for small molecules and then phage. Brittney spent the last several years, in the gene editing space, first at CRISPR Therapeutics and then at Vor Biopharma. In both roles, her focus was on developing novel assays to characterize the editing reagents and delivery modalities with a focus on characterizing gRNA, Cas9, and RNP.

Brittney Pierson

Joe is vice president, editing development at Verve Therapeutics. Working for nearly a decade in the biotechnology industry, Joe brings broad experience in early and late-stage drug development, basic and clinical research, medical affairs, alliance management, and program leadership. Prior to joining Verve, he was vice president, program, and portfolio management at Shape Therapeutics. Joe began his career in medical affairs at Dyax, followed by a number of roles in both medical affairs and program leadership at Bluebird Bio. He received his B.A. in philosophy from the University of Vermont, a PhD in neuroscience from the University of Colorado at Boulder and completed his post-doctoral studies at the Picower Institute for Learning and Memory at MIT and the US Army Research Institute for Environmental Medicine.

Joe Biedenkapp

Zunera is a research associate, gRNA technology at Verve Therapeutics. Prior to joining Verve, Zunera worked as a research technician at Duke University in the Ferrari Lab, working on HIV vaccine clinical trials and plasmid cloning. Zunera received her B.S. in molecular biology from University of Denver, in Colorado. Zunera has 2 years of mammalian cell culture and molecular biology experience.

Zunera Khan

Dhinesh Kannan is a research associate in bioanalytical assay development at Verve Therapeutics, with experience in molecular biology techniques. Prior to joining Verve, Dhinesh worked at Thermo Fisher Scientific. In this role, he served as an analyst for gene therapy products. Dhinesh received his B.Tech in Biotechnology from Anna University, Chennai, and M.S in Pharmaceutical Sciences, with a concentration in Pharmaceutics and drug delivery systems from Northeastern University.

Dhinesh Kannan Srinivasan Kamalakkannan

Troy Lister is senior vice president, Research at [Verve Therapeutics](/org/verve-therapeutics). Troy has more than 15 years’ experience in the biopharmaceutical industry as a medicinal chemist, program and portfolio leader and head of R&D. After stints at Novartis Institute for Biomedical Research and Astra Zeneca, and prior to joining Verve, Dr. Lister was SVP R&D at [Spero Therapeutics](/org/spero-therapeutics) where he helped build the company from 4 employees to over 150 and lead multiple programs into FIH studies and through clinical development. He received his B.Sc. and Ph.D. in organic chemistry from [Flinders University](/org/flinders-university), Australia and completed post-doctoral studies in bioactive natural product total synthesis at The Scripps Research Institute in La Jolla with K.C. Nicolaou.

Troy Lister

Alexandra Cok is the manager, of external quality control at Verve Therapeutics. She has worked in analytical development, CMC, and quality control for the last 5+ years, in the Boston area. Prior to joining Verve, she most recently worked at Mersana Therapeutics, as a scientist in the CMC Analytical department, supporting clinical pipeline products. Previously, she worked at Ocular Therapeutix, in analytical development and quality control. Alexandra received her B.Sc in Chemistry and Mathematics from Calvin College.

Alexandra Cok

Meghan Weinreb is an associate director, internal quality assurance at [Verve Therapeutics](/org/verve-therapeutics).  She has over 12+ years of quality experience, in rare genetic diseases and cancer treatments.  Prior to joining Verve, she worked at bluebird bio in the quality Systems group, implementing Veeva QMS and executing a successful FDA inspection for approval of treatment in patients with multiple myeloma.  She received her Master’s Degree in regulatory affairs for drug development from [Northeastern University](/org/northeastern-university).

Meghan Weinreb

Allen Barrett is the director, corporate counsel at [Verve Therapeutics](/org/verve-therapeutics). Prior to joining Verve, Allen was the legal business partner, to the R&D departments at [Akebia Therapeutics](/org/akebia-therapeutics), Inc. Prior to [Akebia Therapeutics](/org/akebia-therapeutics), Allen supported life sciences research at Partners Healthcare (now [Mass General Brigham](/org/mass-general-brigham)), as an Agreement Associate. He received his J.D., M.B.A., and B.A. from [Suffolk University](/org/suffolk-university).

Allen Barrett

Jennifer Lavoie is director, CMC program management at [Verve Therapeutics](/org/verve-therapeutics), where she leads the CMC team in ensuring program initiatives and goals are reached. She has extensive industry experience in various areas such as program/project management, regulatory affairs, and quality assurance. Most recently, she served as regulatory project manager for [Akebia Therapeutics](/org/akebia-therapeutics), where she was responsible for managing all aspects of regulatory submissions for their lead program as well as developing department unity for a newly created team. Ms. Lavoie received her B.S. in environmental science with a minor in chemistry from [Franklin Pierce University](/org/franklin-pierce-university).

Jennifer Lavoie

Matthew Schmidt is director of regulatory affairs at Verve Therapeutics. He has over 6 years of experience in regulatory strategy, within the life sciences industry across all stages of product development and with multiple therapeutic areas. Prior to joining Verve, Dr. Schmidt was an associate director of regulatory strategy at bluebird bio, Inc. supporting the development and marketing approval of an autologous gene therapy product for a rare genetic disease. Dr. Schmidt earned his Doctor of Pharmacy (Pharm.D.) from Northeastern University and is a Registered Pharmacist in the Commonwealth of Massachusetts. He was a postdoctoral fellow at Genentech, A Member of the Roche Group, in the Rutgers Institute for Pharmaceutical Industry Fellowships Program.

Matthew Schmidt

Allison Dorval is the Chief Financial Officer of [Verve Therapeutics](/org/verve-therapeutics). Ms. Dorval is an experienced financial executive with more than 20 years of leadership experience in finance, accounting and investor relations. Prior to joining Verve, she served as Chief Financial Officer at [Voyager Therapeutics](/org/voyager-therapeutics). She is a member of the Board of Directors at [Aerovate Therapeutics](/org/aerovate-therapeutics) and [Puma Biotechnology](/org/puma-biotechnology). Ms. Dorval previously served as vice president and controller at Juniper Pharmaceuticals, Inc., and as Chief Financial Officer at Insulet Corporation. Ms. Dorval also held corporate finance positions with iBasis, Inc. and Digitas Inc. She is a certified public accountant and began her career in public accounting at PricewaterhouseCoopers LLP. Ms. Dorval obtained a Bachelor of Science in Business Administration from the [University of Vermont](/org/university-of-vermont).

Matthew Redihan

Jen Robinson is the vice president, investor relations and corporate communications at Verve Therapeutics. She has nearly 20 years of strategic communications experience, including 10 years directing investor relations and corporate communications for biopharmaceutical companies. Most recently, Jen was vice president, investor relations and corporate communications at Deciphera Pharmaceuticals. She also was senior director, investor relations and corporate communications at resTORbio and held similar roles at Ra Pharmaceuticals, Ariad Pharmaceuticals and Dyax Corp. Earlier in her career, Jen worked as an equity research analyst on the buy-side, including Putnam Investments, as well as a consultant liaison at Leerink Swann, now SVB Leerink. She received her B.A. from Dartmouth College. 

Jennifer Robinson

Maggie Beaudoin is Vice President, Finance at [Verve Therapeutics](/org/verve-therapeutics). She has 30 years of experience in finance, with 17 years in life sciences. Prior to joining Verve, she held corporate and clinical positions at Fisher Scientific, inVentiv Health and several biotech organizations. In addition to her industry roles, she also held positions in both audit and mergers and acquisitions services at PriceWaterhouseCoopers. Ms. Beaudoin holds a B.A. in economics from the University of Massachusetts Amherst and her CPA license in Massachusetts.

Maggie Beaudoin

Caroline Reiss is an associate principal scientist, RNA technology at Verve Therapeutics, with expertise in production and characterization of RNA molecules. Prior to the joining Verve, Dr. Reiss worked as a development scientist at Casebia Therapeutics, manufacturing mRNA for gene editing therapeutics. She received her B.S. in biochemistry from Trinity College and her Ph.D. in molecular biophysics and biochemistry from Yale University, where she published three X-ray crystal structures of RNA aptamers in complex with their native small-molecule ligands.

Caroline Reiss

Nick is a senior research associate, in process development at Verve. Prior to joining Verve, Nick worked as a biomanufacturer at Aldevron. In this role, he performed the downstream processes involved in large-scale pDNA extraction and purification. He has experience using various forms of resin chromatography and purification methods of nucleic acids. Nick attended North Dakota State University and received a B.S. in Psychology with minors in Chemistry and Neuroscience.

Nick Laschkewitsch

Kevin Weaver is an engineer, process development at Verve Therapeutics. Prior to joining Verve, he worked as an engineer at Alnylam Pharmaceuticals, where he focused on process analytics for commercial manufacturing as well as developing internal pilot scale LNP manufacturing capabilities. Kevin has a B.S. in chemical engineering, with a concentration in biomolecular engineering, from the University of Notre Dame.

Kevin Weaver

Soumya Gangopadhyay is a Associate Principal Scientist, Bioanalysis at Verve Therapeutics with expertise in molecular and cell-based assays. Prior to joining Verve, Dr. Gangopadhyay worked at Intellia Therapeutics, developing several molecular assays for CRISPR-Cas9 based pre-clinical in-vivo and ex-vivo gene editing programs. Dr. Gangopadhyay received her Ph.D. from Syracuse University where she identified the amino acid residues involved in substrate specificity of GGTase-I, an enzyme that post-translationally modifies several Rho GTPases. She then completed a postdoctoral fellowship at the Broad Institute where she worked on developing technologies to modulate Cas9 activity using small molecules and light. 

Soumya Gangopadhyay

Joan Nickerson is senior vice president, human resources and facilities at [Verve Therapeutics](/org/verve-therapeutics) with over 25 years’ experience in human resources.  Prior to joining Verve, she led the HR functions at Dyax Corp., until it was acquired by Shire, and most recently at [Sarepta Therapeutics](/org/sarepta-therapeutics).  Ms. Nickerson holds a BBA from the University of Massachusetts and an MBA from Simmons College in Boston.

Joan Nickerson

Christopher Welch is the director, external manufacturing at Verve Therapeutics.  He has over 15 years of experience supporting both internal and external manufacturing, from clinical to commercial, in the BioPharma Industry.  Prior to joining Verve, Chris worked as the associate director of external operations at Alkermes, Inc., where he was responsible for contract manufacturing of their first biologics-based product.  Chris received a B.S. in chemical engineering from Worcester Polytechnic Institute. 

Chris Welch

Maurine Braun is an Associate Director, Toxicology at Verve Therapeutics. Ms. Braun brings extensive drug development experience with a focus on planning, conducting, and managing GLP-compliant safety studies as well as non-GLP in vivo pharmacology studies across several different drug candidates including small molecule, biologics, and genetic therapies. Prior to joining Verve, Ms. Braun was a senior manager of preclinical development at Avrobio. She has held a number of positions at Wave Life Sciences and Novartis specializing in pharmacology and toxicology. Ms. Braun earned a B.S. with honors in neuroscience from The University of Massachusetts Amherst and an M.S. in biomedical sciences from The University of Massachusetts Medical School.

Maurine Braun

William Tien-Street is an automation engineer, next-generation sequencing at Verve Therapeutics. He has 5 years of experience in the biotechnology and medical device industry. Prior to working at Verve, Will worked as an engineer at Emulate Bio, driving automation and developing Organ-Chip technologies. He received his B.S. in biomedical engineering, with a concentration in cell and tissue engineering, from Northeastern University.

William Tien-Street

Aaron Beach is Director, Analytical Development at Verve Therapeutics. He has extensive biochemistry experience with a focus on producing and characterizing recombinant proteins and lipid nanoparticles. Prior to joining Verve, Mr. Beach served as principal scientist and investigator at the Novartis Institute for Biomedical Research, where he spent five years in positions of increasing responsibility. Most recently, Mr. Beach’s work focused on developing robust analytical methods for biological therapeutics and their transfer to clinical development. Previously, he held research positions at Dow AgroSciences and Biogen Idec. Mr. Beach received his B.S. in biochemistry at the University of Dayton.

Aaron Beach

Souvik Biswas is the director, of chemistry and formulation at Verve Therapeutics. He is a synthetic organic chemist with research expertise in the interface of chemistry, nanotechnology and life sciences, also known as nanomedicine. Prior to Verve, Dr. Biswas was a scientist, in the discovery chemistry group at Moderna, where he was actively involved in the development of potent mRNA therapeutics. He earned his M.Sc. from the University of Delhi and his Ph.D. in chemistry at the University of Louisville, where his thesis research was focused on developing novel magnetic and lipid nanoparticles for nucleic acid delivery. Dr. Biswas’ research also led to the founding of Breath Diagnostics. Dr. Biswas conducted his postdoctoral research at the University of British Columbia and completed his postdoctoral fellowship at the National Cancer Institute.

Souvik Biswas

Zachary Glass is a Scientist at [Verve Therapeutics](/org/verve-therapeutics), with a background in biomedical engineering. He recently received his Ph.D. from [Tufts University](/org/tufts-university), where his research focused on nanoparticle delivery of biomacromolecules in vivo. Prior to that, his research experiences included tissue engineering, neuronal stem cell biology, and cardiovascular biology. Dr. Glass received his B.S. and M.Eng., both in biomedical engineering, from [Cornell University](/org/cornell-university). 

Zachary Glass

Ash Nagpal is a senior process engineer at [Verve Therapeutics](/org/verve-therapeutics) specializing in scale-up and tech transfer. Prior to joining Verve, Mr. Nagpal worked as a process engineer at [Moderna Therapeutics](/org/moderna-therapeutics), developing and supporting large scale manufacturing of lipid nanoparticles for mRNA-based therapeutics. He earned his B.S. and M.S. in chemical engineering from [Worcester Polytechnic Institute](/org/worcester-polytechnic-institute).



Ash Nagpal

Andrew Dorsey is a formulation research associate at [Verve Therapeutics](/org/verve-therapeutics). Prior to joining, Andrew completed two co-ops; first with [Lyndra Therapeutics](/org/lyndra-therapeutics), contributing to formulation work for extended drug release in schizophrenia and Alzheimer’s projects and the other with [Takeda Pharmaceutical](/org/takeda-pharmaceutical), in the process chemistry and development group, where he led solubility studies and validation of equipment for the evaluation of alternative step solvents, as well as, assisted with green chemistry evaluation of department projects. He earned a B.S and M.S. in chemical engineering from [Northeastern University](/org/northeastern-university). 

Andrew Dorsey

Anne Marie Mazzola is a Study Manager at Preclinical Pharmacology and Toxicology at Verve Therapeutics. She brings many years of preclinical pharmacology experience in large pharma and biotech with both biologics and small molecules. She spent a significant portion of her career at AstraZeneca Pharmaceuticals developing clinically relevant models of human cancers, including patient-derived xenograft models, to better inform clinical dosing strategies for drug candidates. Immediately prior to joining Verve, Ms. Mazzola was a scientist at Elstar Therapeutics, where she was integral in growing the pharmacology team and building key capabilities to evaluate immuno-oncology drug candidates. Ms. Mazzola has also held positions at Millennium Pharmaceuticals and Novartis Institute for Biomedical Research. She holds a B.Sc. in animal science from The University of Massachusetts Amherst.

Anne Marie Mazzola

Scott Vafai is executive director, translational medicine at [Verve Therapeutics](/org/verve-therapeutics), where he provides clinical and translational leadership to drive the design and interpretation of Verve’s clinical programs. Prior to joining Verve, Dr. Vafai was senior director of translational medicine and clinical pharmacology at [Sanofi](/org/sanofi) with a focus on gene therapy. During his time at [Sanofi](/org/sanofi), he was responsible for advancing an AAV gene therapy program from research into a first-in-human study. Prior to [Sanofi](/org/sanofi), Dr. Vafai directed an industry-funded mitochondrial therapeutics discovery group at the [Broad Institute](/org/broad-institute). He is a co-founder of [Metavention](/org/metavention), a clinical stage company developing hepatic denervation for the treatment of type 2 diabetes. Dr. Vafai completed his residency in internal medicine at Brigham and Women’s Hospital and fellowship in endocrinology at Massachusetts General Hospital. His post-doctoral training was focused on mitochondrial biology with Dr. Vamsi Mootha at Massachusetts General Hospital and the [Broad Institute](/org/broad-institute). He holds an M.D. from the Harvard-MIT Health Sciences and Technology Program and an A.B. in molecular biology from [Princeton University](/org/princeton).

Scott Vafai

Padma Malyala is Vice President, Pharmaceutical Sciences at [Verve Therapeutics](/org/verve-therapeutics). She has nearly 20 years’ experience in formulation and characterization of complex biotherapeutics at [Novartis](/org/novartis), GSK and MedImmune-AstraZeneca. Most recently, Ms. Malyala served as head of the formulation and characterization group for Biologics at [Novartis](/org/novartis) Institute for Biomedical Research (NIBR), where she was responsible for de-risking the development process and transition well defined robust drug products to the clinic. She was also a key member of due diligence teams to strengthen the drug product science, as well as the immuno- oncology portfolio. As global head, pharmaceutical sciences in technical R&D at GSK, she managed technology transfer of the RNA-LNP platform technology to development, using QbD principles. Previously, Ms. Malyala served as group leader, formulations at MedImmune – AstraZeneca and as global head-pharmaceutical sciences at [Novartis](/org/novartis) Vaccines. She is the author of multiple patents, publications and book chapters in the field of formulation, characterization and delivery systems. Ms. Malyala received both her B.S. in Pharmaceutical Sciences and M.S. in Pharmaceutical Chemistry (Gold Medalist) from Andhra University in India.

Padma Malyala

Emily Cronin is the associate director, benefits at Verve Therapeutics. Emily has over 15 years of experience leading benefits and payroll, in real estate management and hospitality organizations.  Prior to joining Verve, she Emily was the director of benefits and payroll for Winn Management Group, one of the largest military and affordable housing real estate managers in the country.  Emily received her B.S. in hotel management and business from the University of New Hampshire and has her certified employee benefits specialist certificate through the International Foundation of Employee Benefits and the Wharton School of University of Pennsylvania.

Emily Cronin

Yuri Matsumoto is Associate Director, Bioanalysis at Verve Therapeutics, with expertise in bioanalytical assay development for discovery, preclinical and clinical applications. Prior to joining Verve, Dr. Matsumoto worked on protein engineering of Cas9 and research assay development at Intellia Therapeutics. Prior to Intellia, Dr. Matsumoto worked on preclinical and clinical assay development of a monoclonal antibody therapy to treat diabetic macula edema at Eleven Biotherapeutics. Dr. Matsumoto received her Ph.D. in biological engineering from MIT, where she harnessed the power of directed evolution to engineer a highly magnetic ferritin mutant to serve as a genetically-encodable MRI contrast agent.

Yuri Matsumoto

Jeff Molles is the senior director, clinical data management at Verve Therapeutics. He has over 20 years of experience in data management. Prior to joining Verve, Jeff was head of the data management team at Alnylam Pharmaceuticals, for the last 7 years, contributing to the successful submission and approval of three marketed products in rare disease. He received a B.A. degree in psychology from Bowdoin College.

Jeffrey Molles

Chelsey Jensen is the director, clinical operations at [Verve Therapeutics](/org/verve-therapeutics). She has nearly 15 years of clinical operations experience across all phases of clinical research and spanning many therapeutic areas, with a focus in rare disease and cardiometabolic disorders. Prior to joining Verve, Chelsey provided clinical program oversight for several cardiovascular disease and rare disease development programs at [Ionis Pharmaceuticals](/org/ionis-pharmaceuticals) and Akcea Therapeutics. She began her career at [Vertex Pharmaceuticals](/org/vertex-pharmaceuticals), where she was a key member of the study team, responsible for the clinical development, filing, and successful approval of a first in class cystic fibrosis drug. Chelsey received her B.S. in biochemistry and biophysics from [Rensselaer Polytechnic Institute](/org/rensselaer-polytechnic-institute) in Troy, NY.

Chelsey Jensen

Amy Li is a clinical trial specialist at Verve Therapeutics. Prior to joining Verve, she worked as a clinical research associate on hATTR polyneuropathy trials at Ionis Pharmaceuticals and on phase 2 clinical programs targeting APOCIII and ANGPTL3 at Akcea Therapeutics, as a clinical trial associate. Amy received her B.S. in Biology and Community Health from Tufts University and her M.P.H. in Epidemiology from Boston University.

Amy Li

Angela Cook is senior manager, culture and administration at [Verve Therapeutics](/org/verve-therapeutics). With more than a decade of experience in operational and administrative management, Mrs. Cook provides oversight and guidance on day-to-day functions to organize strategic priorities and create operational efficiency. Prior to joining Verve, she served as senior administrative manager, in the Center for Genomic Medicine at Massachusetts General Hospital, where she was responsible for facilitating and executing the Center’s newly developed strategic plan. Ms. Cook received her Bachelor’s degree in sociology and criminal justice studies from [Rhode Island College](/org/rhode-island-college).

Angela Cook

Carina Nyberg Washington is an executive assistant supporting the general administration at Verve Therapeutics. She has 15 years of experience in administration, with 5 years in a support role. Prior to joining Verve, she worked as an executive assistant to the CEO at WS Development. Ms. Nyberg Washington received her diploma in orchestral performance from The Royal Danish Conservatory of Music and her Master, in orchestral performance from the University of Memphis. She co-founded the non-profit organization PRIZM Ensemble, which uses classical music as a tool for youth development.

Carina Nyberg Washington

Sheila Mikhail has over 20 years of biopharmaceutical leadership experience and currently serves as chief executive officer and co-founder of AskBio, a company she started in 2001. Prior to her current role, she served as chief executive officer and co-founder of Bamboo Therapeutics, where, under her direction, the company raised $50 million, advanced a therapeutic for giant axonal neuropathy, a rare genetic disorder, into the clinic, completed pre-IND studies for a Duchenne muscular dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by [Pfizer](/org/pfizer) in August 2016 in a deal valued at $827 million. Prior to that, she was part of the management team at Chatham Therapeutics, which was acquired by Baxter in 2014. Ms. Mikhail practiced law for more than 15 years, during which time she founded Life Sciences Law, which serviced clients including [Bayer](/org/bayer), Gilead, GlaxoSmith Kline, [Sanofi](/org/sanofi) and Aventis. She also practiced with Ropes and Gray in Boston. Ms. Mikhail holds a J.D. from [Northwestern University](/org/northwestern-university), an MBA from the University of Chicago and a B.S. from the University of Illinois at Urbana-Champaign.

Sheila Mikhail

Jeff Meltzer is the vice president, of quality at Verve Therapeutics. Jeff has 25+ years of experience building successful teams, that implement effective GXP pharmaceutical Quality Management Systems. Prior to joining Verve, Jeff led the quality function for Affinia Therapeutics, Prevail Therapeutics, Trevena and PMRS. He has also worked at Bristol Myers Squibb and Alvogen. In these previous roles, he contributed to a broad range of INDs and commercial products. He obtained a Certified Pharmaceutical Industry Professional (CPIP) credential from ISPE and holds a BS and MS in industrial engineering from Lehigh University.

Jeffrey Meltzer

Victoria Bartlett is Vice President, Alliance and Program Management at Verve Therapeutics. She has over 20 years of industry experience, predominantly in program, alliance, and portfolio management. Dr. Bartlett joins us from Ionis Pharmaceuticals, where she worked as senior director of alliance management and was responsible for the Ionis partnerships within the cardio-renal franchise. Prior to that, Dr. Bartlett was with Akcea Therapeutics, as senior director of program and alliance management, where she led the phase 2 clinical programs for three antisense oligonucleotide programs targeting Apo(a) (pelacarsen), ANGPTL3 (vupanorsen), and APOCIII. In addition, she held program, alliance, and portfolio positions at CRISPR Therapeutics, Moderna, Pfizer and Wyeth Research. Dr. Bartlett has both a Ph.D. and B.Sc. in Pharmacology from the University of Liverpool and she spent 4 years as a postdoctoral fellow at Harvard Medical School. 

Victoria Bartlett

Yasser El-Gamal (“Yas”) is Vice President of Legal Affairs and Chief Intellectual Property Counsel of [Verve Therapeutics](/org/verve-therapeutics).  Yas comes to Verve with over 25 years of experience in advising technology companies on a broad spectrum of business and legal matters.  He has law, engineering, and biotechnology degrees, is admitted to practice in numerous federal and state courts and administrative agencies and is a registered patent attorney.  Prior to joining Verve, Yas was a member of top-rated national and international law firms, where he served in various capacities, including as office Partner-in-Charge and Chair and Co-chair of several practices.

Yasser El-Gamal

Sara Garcia is Associate Principal Scientist, Computational Biology at Verve Therapeutics with expertise in genome editing safety. Prior to joining Verve, she was a computational biologist in the Molecular Pathology Unit at Massachusetts General Hospital, where she conducted research in the areas of genome editing and cancer. She completed research fellowships at the Dana-Faber Cancer Institute, Harvard T.H. Chan School of Public Health, and the University of Cambridge. Dr. Garcia received her Ph.D. in biology from the New University of Lisbon, where she studied the dynamics of biological systems from time series. She has authored or contributed to more than 30 research papers.

Sara Garcia

Ryan Stoeckel is the Associate Director, Procurement at [Verve Therapeutics](/org/verve-therapeutics). In this role, he leads the organization’s procurement function, with a focus on streamlining purchasing systems and processes; as well as, improving spend optimization.  He has over 12 years experience in strategic sourcing and procurement, with the last 5 years spent in pharma/biotech.  Prior to joining Verve, he worked as a procurement technology category lead at [Foundation Medicine](/org/foundation-medicine).  Mr. Stoeckel received his B.A. in Business Administration from [Northeastern University](/org/northeastern-university) and his MBA from [Norwich University](/org/norwich-university).

Ryan Stoeckel

Hari Jayaram is vice president, editing and discovery at [Verve Therapeutics](/org/verve-therapeutics). He trained as a structural biologist and biochemist, starting with his PhD, working on viral RNA binding proteins at [Baylor College of Medicine](/org/baylor-college-of-medicine) and postdoc at Brandeis university, working on membrane protein transporters. His scientific expertise spans from structure guided drug discovery and computational biology to protein engineering and gene editing. Prior to Verve, he played a foundational role in building [Spotlight Therapeutics](/org/spotlight-therapeutics) as its first employee and VP of Technology. At Spotlight, he was responsible for hiring the initial scientific team, establishing the science capabilities from the ground up and lead the development of its platform approach to create a new class of Biologics for targeted in vivo delivery of CRISPR Ribonucleoproteins. Dr. Jayaram was also one of the early scientists at [Editas Medicine](/org/editas-medicine) where he built and led Editas’ computational Biology and Ribonucleoprotein engineering groups. Dr. Jayaram began his career in industry at [Constellation Pharmaceuticals](/org/constellation-pharmaceuticals) where as a member of the drug discovery group he played an integral role in [Constellation](/org/constellation-inc)’s clinical programs and research collaboration developing small molecules to harness epigenetic mechanisms to treat cancer.

Dr. Jayaram has over 20 scientific publications and over 20 issued and pending patents. He received his BSc from the University of Bombay, MSc from Indian Institute of Technology, PhD from [Baylor College of Medicine](/org/baylor-college-of-medicine) and post docs at both [Baylor College of Medicine](/org/baylor-college-of-medicine) and [Brandeis University](/org/brandeis-university).

Hari Jayaram

Erin Hood is the Senior Contracts Specialist, in the Legal Department, at Verve Therapeutics. She has over ten years of experience in legal operations and contract life cycle management. Prior to joining Verve, she worked as the Legal Operations Coordinator at AMAG Pharmaceuticals, Inc. Ms. Hood is currently finishing up an Associates Degree in Paralegal Studies at Quincy College.

Erin Hood

Richard Lee

Johnathan Petit

Seka Lazare is the current Associate Director of Next Generation Sequencing at [Verve Therapeutics](/org/verve-therapeutics). Seka has always been passionate about biology and genetics and has worked in the field for over 10 years. Seka started their career as a Research Associate at [Illumina](/org/illumina), where they worked for three years before becoming a Manager of Scientific Research. In this role, they oversaw a team of scientists and was responsible for developing and executing research projects.

In 2018, Seka left [Illumina](/org/illumina) to take on a new challenge as a Postdoctoral Researcher at La Jolla Institute for Allergy and Immunology. In this role, they implemented and managed in vivo functional stem cell and immunology studies. Seka also gene manipulated via CRISPR and lentiviral techniques to model SNPS and gene candidates.

Seka is an expert in their field and has published several papers in peer-reviewed journals. In addition to their scientific work, Seka is also an active speaker and has presented their work at international conferences.

Seka Lazare reports to Sekar Kathiresan, Co-Founder & CEO. They work with Andrew Bellinger - Chief Scientific Officer & Chief Medical Officer, Derek Sethachutkul - Senior Director, External Manufacturing, and Leslie Stolz - SVP, Regulatory Affairs.

Seka Lazare

Jax Shay is a research associate working on formulation and characterization of lipid nanoparticles at Verve Therapeutics. They have over two years of analytical chemistry experience in the pharmaceutical and biotech industries. Prior to Verve, they worked as an analytical research associate at Vertex, doing high-throughput purification and characterization of drug substances and intermediates. Maddy received their B.S. in chemistry from Northeastern University, where they contributed to research developing small molecules for the treatment of neglected tropical diseases.



Jax Shay

Michael Gilman is an associate principal engineer, in process development at Verve Therapeutics. Prior to joining Verve, Michael worked at Moderna, in manufacturing sciences and technology supporting COVID vaccine manufacturing, and earlier in mRNA process development. Previously, he also held roles in clinical and commercial manufacturing at Alexion. He has a master’s degree in cell and bioprocess engineering from Tufts University and a bachelor’s degree in chemical engineering from the University of New Hampshire.

Michael Gilman

Liam Cornell is a senior scientist, editing and discovery at Verve Therapeutics. He has over 10 years of molecular biology experience, in academia and the biotechnology industry. Prior to joining Verve, he worked as a scientist at CRISPR Therapeutics, where he supported hematology and in-vivo programs. He received his Ph.D., in molecular oncology, from Newcastle University, UK. Here, he researched the role of DNA repair in liver cancer and showed the potential therapeutic benefit of its inhibition. He then completed a post-doctoral fellowship at the Dana-Farber Cancer Institute where he discovered a novel resistance mechanism to CDK4/6 inhibitors in breast cancer.

Liam Cornell

Kim Milliken is the current Senior Director of Regulatory CMC at [Verve Therapeutics](/org/verve-therapeutics). Kim has over 25 years of experience in the field of Regulatory Affairs and Quality Control. 

Kim started their career in 1991 as a Microbiology Planter at Path Lab. Kim then moved to [Biogen](/org/biogen) in 1993 as a QC Analyst. In 1995, they became QC Microbiology Manager at Lonza Biologics, Inc., and in 2003 they became Head of QC at Lonza AG in Visp, Switzerland. Kim returned to Lonza Biologics in 2005 as Director of Regulatory Affairs and held that position until 2016 when they joined Takeda as Senior Director Regulatory, CMC. Kim has been with [Verve Therapeutics](/org/verve-therapeutics) since October 2016.

Kim Milliken reports to Kallanthottathil G. Rajeev, VP, CMC. Some of their coworkers include Jennifer Lavoie - Director, CMC Project Management.

Kim Milliken

Athul Sanjeev is a Senior Research Associate at [Verve Therapeutics](/org/verve-therapeutics), where they focus on RNA technology. Athul has also interned at Intellia Therapeutics, Inc., where they produced Cas9 mRNA and performed its characterization. Athul has also worked as an Entrepreneurial Lead at NSF I-Corps, where they performed customer discovery for spinning out a start-up from Prof. Sunny Zhou's lab at [Northeastern University](/org/northeastern-university). Athul has also worked as a Graduate Researcher at Sunny Zhou Lab and as a Graduate Research Assistant at the Antimicrobial Discovery Centre.

Athul Sanjeev has a Master of Science from [Northeastern University](/org/northeastern-university) in Biotechnology and a Bachelor of Technology from University of Kerala in biotechnology and biochemical engineering. Athul also has certifications from LinkedIn in Developing Executive Presence, Lead Like a Boss, and Strategic Thinking.

They work with Nick Laschkewitsch - Senior Research Associate, Process Development, Paris James - Senior Research Associate, RNA Technology, and Michael Shen - Research Associate, Process Development. Their manager is Christopher J. Cheng, VP, Process Development & RNA Technology.

Athul Sanjeev

Robin Eisner is currently the Facilities Operations Manager at [Verve Therapeutics](/org/verve-therapeutics). Robin has over five years of experience in managing office operations and has played an integral role in the expansion of several businesses. 

Prior to joining Verve, Robin was the Manager of Office Operations at [Rubius Therapeutics](/org/rubius-therapeutics) where they oversaw all aspects of the lab and office, including purchasing, receiving, inventory control, vendor relations, and maintenance and repairs of equipment and facility. Robin also assisted with the processing of accounts payable and was responsible for on-boarding and off-boarding of employees, event and meeting planning, and expense reconciliations. In addition, Robin served as a liaison between Rubius and venture capital firms, property management companies, IT consultants, purchasing vendors and consultants. 

Before their time at Rubius, Robin was the Global Executive Assistant at Hay Group where they provided administrative support to a team of executives. In this role, Robin managed calendars, travel arrangements, expense reports, and meeting coordination. 

Robin began their career as an Administrative Coordinator at Harvard Medical School where they provided administrative support to the Department of Neurology. In this role, Robin managed department budget, scheduling, and events coordination. 

Robin Eisner is a highly skilled administrative professional with a proven track record in supporting businesses operations. Robin’s experience in managing office operations, event planning, and budgeting make their an asset to any organization.

Robin Eisner reports to Joan Nickerson, SVP, HR & Facilities. Robin Eisner works with Robyn Naigles - Human Resources Specialist, Kaitlin Duffy - Senior Director, HR, and Angela Cook - Senior Manager, Culture & Administration.

Robin Eisner

Pradeep Tangallapally is a Senior Analyst of Quality Control at [Verve Therapeutics](/org/verve-therapeutics). Pradeep has over seven years of experience in the biotech industry. 

Pradeep started their career as an Analytical Chemistry Co-op at Cubist Pharmaceuticals in January 2012. There, they provided research support for several projects, including running assays and method development for HPLC separation. Pradeep then became a NMR Co-op at Cubist Pharmaceuticals in January 2013 and held that position until August 2014. 

In June 2015, Pradeep started working as a Senior Research Associate on the Biophysical & Formulation Team at Moderna. Pradeep worked there until February 2022 when they transitioned to their current role as a Senior Analyst of Quality Control at [Verve Therapeutics](/org/verve-therapeutics).

Pradeep Tangallapally has a Bachelor of Science in Chemistry from [Northeastern University](/org/northeastern-university).

Pradeep Tangallapally reports to Jeffrey Meltzer, VP, Quality. Pradeep Tangallapally works with Leocadia Ruiz - Senior Director, External Quality Control, Angela Gleason - Manager, Internal Quality Assurance, and Amanda Charlesworth - Manager, External Quality Control.

Pradeep Tangallapally

Anson Le is a research associate, and analytics at Verve Therapeutics. He holds a B.S. in Biological Sciences from the University of Massachusetts, Lowell, where his focus was biochemistry and molecular biology. Prior to joining Verve, he worked in the genomics platform at the Broad Institute of MIT and Harvard, assisting in their COVID-19 testing effort. Prior to the Broad, he was an academic tutor for chemistry, organic chemistry, and biochemistry at his alma mater, where he also contributed to novel arachnid research and documentation.

Anson Le

Allison Dorval is the current Chief Financial Officer at [Verve Therapeutics](/org/verve-therapeutics). Prior to their current role, Allison served as the Vice President of Controller at Juniper Pharmaceuticals, Inc., the Chief Financial Officer at Voyager Therapeutics, Inc., and as a Consultant at Danforth Advisors.

Allison has significant experience in accounting, financial reporting, SEC compliance, Sarbanes-Oxley compliance, and tax compliance. Allison has also played a key role in multiple financing transactions and has managed the close process for several companies.

Allison's experience in the life sciences industry has allowed their to provide key financial and operational support to senior management teams, freeing them up to focus on driving science and technology value for their stakeholders.

Allison Dorval has a graduate certification in Taxation from Bentley University - McCallum Graduate School of Business, a Bachelor of Science in Accounting from [University of Vermont](/org/university-of-vermont), and is a Certified Public Accountant.

Some direct reports include Maggie Beaudoin - VP, Finance, Jennifer Robinson - VP, Investor Relations & Corporate Communications, and Nolan Yu - Senior Director, Financial Planning & Analysis. They work with Troy Lister - SVP, Research, Yasser El-Gamal - VP, Legal Affairs & Chief Intellectual Property Counsel, and Bryan Macdonald - Director, Pharmacology & Toxicology. Allison Dorval reports to Sekar Kathiresan, Co-Founder, CEO & Board Member.

Allison Dorval

Maria is a receptionist and administrative office associate at Verve Therapeutics, with over 15 years of experience, as an administrative professional. Prior to joining Verve, Maria was the office manager for the Shire, formally Dyax. Ms. Murray has extensive experience in customer service, project coordination, and vendor management.

Maria Murray

Felix Acheampong is a Senior Scientist, Mass Spectrometry at Verve Therapeutics. He brings over five years of pharma/biotech experience; having worked on multiple drug modalities. Prior to Verve, he contributed to discovery and development programs at Novartis (isolating and characterizing natural products using high-resolution mass spectrometry), Agios (developing untargeted lipidomics methodologies), and PPD (developing and validating methods for small molecule bioanalysis using LCMS). He believes that, whether serendipitous or non-serendipitous, all his novel discoveries were achieved by laboratory dedication. Dr. Acheampong received his bachelor’s and master’s degrees from the Kwame Nkrumah University of Science and Technology (KNUST) in Kumasi, Ghana, and his Ph.D. from the South Dakota State University in Brookings, South Dakota. He has published several articles related to the use of mass spectrometry for identifying and characterizing small molecule natural products.

Felix Acheampong

Kui Wang is Associate Principal Scientist, RNA Technology at Verve Therapeutics, where he leads mRNA manufacturing for the company. He has in-depth experience in drug delivery, nanomaterials, and gene therapy. Prior to Verve, he was a scientist at Casebia Therapeutics, where he was responsible for mRNA production and LNP formulation. He has authored and co-authored more than 40 publications. Dr. Wang earned a dual Ph.D. in materials science and engineering and nanotechnology and molecular engineering from the University of Washington. He completed his postdoctoral training at the Massachusetts Institute of Technology and Brigham and Women’s Hospital.

Kui Wang

David Landry is a senior manager of external quality assurance at Verve Therapeutics. He has 10+ years of experience supporting cGMP operations, with 3 years in cell and gene therapy. Prior to joining Verve, he worked at CRISPR Therapeutics as a quality assurance manager, supporting internal operations, batch disposition, and raw materials. Previously, he worked at Vertex Pharmaceuticals, and Shire Pharmaceuticals supporting manufacturing and materials management.

David Landry

Verena Karsten is the senior director, clinical research at Verve Therapeutics. She has over 20 years’ experience in clinical development. Prior to joining Verve, she worked at Vion Pharmaceuticals, Alnylam Pharmaceuticals and CRISPR Therapeutics. Verena received her Diploma and Ph.D. in biology from the Free University in Berlin.

Verena Karsten

Namrata Nammi is a scientist, and analytics at Verve therapeutics, with over nine years of diverse experience, ranging from discovery to analytical development. Prior to joining Verve, she worked as a senior research associate, in analytical development, at Editas Medicine. Here, she contributed to RNP analytical assay development and supported the characterization and release of GMP material for the sickle cell and immune-oncology programs. Prior to Editas, she worked in discovery research at Pfizer and Biogen. Namrata has a master’s degree in Biomedical Science from Northeastern University and a bachelor’s degree in pharmacy from Andhra University in India.

Namrata Nammi

Leya Siddiqui is a research associate in analytical chemistry at Verve Therapeutics. Prior to joining Verve, she was a student at Northeastern University, where she completed three co-ops, in the biotechnology industry. She has worked in the analytical and process development groups at Lyndra Therapeutics, Dragonfly Therapeutics, and most recently, Oncorus. Leya received her B.S. in Chemical Engineering from Northeastern University.

Leya Siddiqui

Alline Pacheco is a senior scientist at [Verve Therapeutics](/org/verve-therapeutics) with expertise in cell-based assays and CRISPR/Cas9 screening. She brings 8 years of research experience both in academia and industry, in the fields of infectious diseases, microbiome, metabolism, and immuno-oncology. Dr. Pacheco has authored and co-authored a dozen publications. Prior to joining Verve, she has held positions at [Evelo Biosciences](/org/evelo-biosciences) and more recently, at [Intellia Therapeutics](/org/intellia), where she developed a platform for CRISPR screening in primary cells, to help advance ex-vivo gene editing programs.  Dr. Pacheco received a Ph.D. in molecular microbiology from UT Southwestern where she discovered a fucose sensing system that connected pathogen, microbiota and the host during intestinal infection. She completed post-doctoral training at UC Davis, Brigham and Women’s Hospital and Harvard Medical School, interrogating host-microbe interactions using transcriptomics, metabolomics and CRISPR/Cas9 screening approaches.

Alline Pacheco

Christina Hao is a senior scientist, editing and discovery at Verve Therapeutics. She has over 10 years of molecular biology and bioinformatics experience, with a specialization in applications of Next Generation Sequencing (NGS) in human genetics. Prior to joining Verve, she worked as a scientist at NuProbe Inc., where she designed and commercialized highly multiplexed NGS panels for detecting low allele frequency mutations in oncology samples. She received her Ph.D. in molecular biology from Boston University. Her thesis focused on the mechanisms of RNA interference and epigenetic control in liver physiology.

Christina Hao

Derek Sethachutkul is Senior Director, External Manufacturing at Verve Therapeutics. He has over 25 years of experience in pharmaceutical development, operations, and program management. Prior to joining Verve, he was a Program Management Lead for the product operations group at Takeda. Mr. Sethachutkul received his B.S. in Pharmacy from Long Island University and his M.B.A. from Bridgeport University. He is a registered pharmacist and has a PMP certification.

Derek Sethachutkul

Harlisa Minaya is a Senior Human Resources Generalist at Verve Therapeutics. She has over 10 years of experience in Human Resources within the hospitality and life sciences fields. Prior to joining Verve, she worked as a human resources partner at the Broad Institute of MIT and Harvard. Ms. Minaya received her B.A. in sociology from the University of New Hampshire. She has also maintained her SHRM-CP since 2018.

Harlisa Minaya

Alex DiMario is the senior manager, of supply chain and logistics at Verve Therapeutics. He has over 11 years of experience in the supply chain, including 7 years within the biotechnology industry. Prior to joining Verve, Alex was a clinical supply manager at Biogen, where he coordinated drug supply for various clinical trials. He has also held roles in clinical logistics, as well as, external manufacturing. Alex earned his B.S. in business administration from Bryant University.

Alex DiMario

Jessica Mangano is a Senior Engineer, Process Development at Verve Therapeutics. She has over seven years of experience in the pharmaceutical industry. Prior to joining Verve, Jessica worked at bluebird bio supporting external manufacturing and commercial launch activities. Previously, she progressed in the formulation and process development of clinical stage hydrogel delivery therapies at Ocular Therapeutix. Jessica received her B.S. in chemical engineering from Northeastern University.

Jessica Mangano

Hoda Rajabi is a scientist, next generation sequencing at Verve Therapeutics. She is a molecular biologist, with over 8 years of experience in a variety of different research laboratories. Prior to joining Verve, she worked as a laboratory scientist at eDNAtec (the first center for environmental genomics application in the world), where she led multiple projects on optimizing and executing NGS-related workflows on environmental samples. She holds a BSc. in cellular and molecular biology from Azad University in Iran, and an MSc. in Human Genetics, from the Memorial University of Newfoundland in Canada. Her Master’s thesis, which was to design, optimize and validate a panel to detect patients with a form of a hereditary macular degeneration disease (STGD1), had a significant role in better diagnosis of patients in the population of Newfoundland and Labrador.

Hoda Rajabi

Lisa Kasiewicz is an associate principal scientist, and formulation at Verve Therapeutics with expertise in RNAi, gene therapy, and lipid nanoparticle nucleic acid delivery technology. She received her Ph.D. in chemical engineering from Carnegie Mellon University, where her research into diabetic wound healing transitioned into how nanoparticle design can enhance delivery to or avoid interaction with the immune system. Dr. Kasiewicz received her B.S. in chemical engineering from Columbia University.

Lisa Kasiewicz

Srinidhi Sridhar is a scientist, editing and discovery at Verve Therapeutics. She has 5+ years of experience in the biotechnology industry, specializing in cellular and molecular biology, tissue culture, drug screening, and gene editing. Prior to joining Verve, she worked at Q-State Biosciences and Beth Israel Deaconess Medical Center (Harvard Medical School). Ms. Sridhar received her bachelor’s degree in Biotechnology from Anna University, India, and her Master’s degree in Biotechnology from the University at Buffalo (State University of New York).

Srinidhi Sridhar

Jeong-Ah Kwon is a Scientist, RNA Analytics at [Verve Therapeutics](/org/verve-therapeutics) with extensive experience in molecular biology and NGS. Prior to joining Verve, Jeong-Ah worked as an analytical scientist at [Homology Medicines](/org/homology-medicines) characterizing AAV-based drug products and introduced a long-read sequencing platform. Prior to Homology, she worked on DNA target enrichment method development using CRISPR/Cas9 system and Oxford Nanopore sequencing at Genetics Research LLC. She has also held research positions at [QIAGEN](/org/qiagen), [Novartis](/org/novartis), Whitehead Institute and [University of Pittsburgh](/org/university-of-pittsburgh). She received her B.S. in Science Education from Ewha Womans University in Korea, and her M.S. in Molecular Biology from [Seoul National University](/org/seoul-national-university) and from [Carnegie Mellon University](/org/carnegie-mellon-university).

Jeong-Ah Kwon

James Cox is an associate scientist, in analytical development = at Verve Therapeutics. Prior to joining Verve, James worked in the biophysical & formulation team at Moderna Inc., where he developed methods to characterize next-generation LNP formulations. James received his B.S. in chemistry from Northeastern University.

James Cox

Michael is a research associate, in process development at Verve Therapeutics. Prior to Verve, he worked in a computational neuroscience lab, at the University of Michigan investigating attentional-motor dysfunction in mouse models of Alzheimer’s disease. He has previous experience with process development, scale-up, and improvement with Sherwin Williams. Michael attended Johns Hopkins University, where he received his B.S in chemical and biomolecular engineering, with a minor in entrepreneurship and management.

Michael Shen

Victoria Clendaniel is a Senior Research Associate, Preclinical Pharmacology at Verve Therapeutics. Most recently, she worked as a research assistant at Beth Israel Deaconess Medical Center (BIDMC), where she researched HDAC3 inhibition as a therapeutic treatment for experimental stroke. Ms. Clendaniel gained experience as an undergraduate researcher at BIDMC, where she contributed to research on Alzheimer’s disease, dementia, and Parkinson’s disease. She received her B.S. in biology, with a concentration in health sciences, from Emmanuel College.

Victoria Clendaniel

Yongli Gu is a scientist II, bioanalysis at [Verve Therapeutics](/org/verve-therapeutics), with expertise in bioanalytical assay development for preclinical studies, molecular biology, biochemistry, and cell biology. Prior to joining Verve, Yongli worked on anti-drug antibody assays, protein binding assays, and assay development at [Alnylam Pharmaceuticals](/org/alnylam-pharmaceuticals). Prior to Alnylam, Yongli worked on assay development and compound screening for Alzheimer’s disease at Brigham and Women’s Hospital. Yongli received her M.S. in Biochemistry from [Kansas State University](/org/kansas-state-university). 

Yongli Gu

Yunxiang “Sean” Dai is a scientist II, mass spectrometry at Verve Therapeutics, with expertise in proteomics. He has three years of pharma/biotech industry experience, in advancing proteomic strategies for discovery research and translational development of multiple drug modalities. Prior to joining Verve, he worked on developing mRNA therapeutics for cystic fibrosis and mRNA vaccines for infectious diseases at Translate Bio, a Sanofi Company. Dr. Dai received his B.A. from St. Olaf College, with double majors in biology and chemistry. He earned his Ph.D., in biophysics, from the University of Wisconsin-Madison, where he published several articles on using mass spectrometry for proteoform identification and proteoform family construction.

Yunxiang Dai

Luis Macias is a scientist, mass spectrometry at [Verve Therapeutics](/org/verve-therapeutics), with expertise in biomolecular structural elucidation. Prior to joining Verve, he worked in the Brodbelt lab, as a graduate student fellow to develop photodissociation-based mass spectrometry methods to structurally characterize proteins and lipids. Dr. Macias received his BS, in chemistry from [Houston Baptist University](/org/houston-baptist-university) and his Ph.D., from the University of Texas at Austin.

Luis Macias

Anthony Federico is a scientist, and bioinformatics at Verve Therapeutics. Prior to joining Verve, he developed computational methods for gene regulatory network reconstruction, in the context of cancer genomics. He received his B.S in biochemistry and molecular biology from the University of Massachusetts and his Ph.D. in bioinformatics at Boston University.

Anthony Federico

Ellen Rohde is the current VP of Pharmacology & Toxicology at [Verve Therapeutics](/org/verve-therapeutics). Prior to this, they were the Senior Director of Biodistribution & Pharmacokinetics at [Intellia Therapeutics](/org/intellia) where they explored the PK/PD and biodistribution of gene editing therapeutics based on Crispr/Cas9 mechanisms. Ellen has also worked as the Director of Analytical Chemistry & DMPK at Cerulean Pharma, Inc and as a consultant at admetconsult_e. Ellen has a passion for studying disposition (metabolism and elimination) of components of lipid nanoparticles, AAV, gRNA, mRNA and measuring and correlating absolute quantities of lipids, RNAs and proteins with effect over time. Ellen is also experienced in modeling PK/PD relationships of gene editing and subsequent protein changes as well as identifying and optimizing LNPs and RNAs and advancing them towards INDs and FIH studies. Ellen is a strong leader, having led a team of 7 scientists with in vivo pharmacology, bioanalytical, modeling & simulation and biomarker expertise. Ellen has also built infrastructure, teams and CRO collaborations in support of Crispr/Cas9 gene editing with annual budgets exceeding $1.5M.

Ellen Rohde received their PhD in Analytical Chemistry from the [University of Cincinnati](/org/university-of-cincinnati) and then went on to complete a postdoc in biological mass spectrometry at the Mayo Clinic School of Medicine. Ellen also holds a Diplomchemikerin degree in Theoretical and Physical Chemistry from Leipzig University, and their research interests include analytical electrochemistry and electrochemical detection methods.

Ellen Rohde reports to Andrew Bellinger, Chief Scientific Officer & Chief Medical Officer. Some of their coworkers include Jeong-Ah Kwon - Scientist, RNA Analytics, Sara Garcia - Associate Principal Scientist, Computational Biology, and Christos Miliotis - Scientist, Editor Development. Some direct reports include Maurine Braun - Associate Director, Toxicology, Bryan Macdonald - Director, Pharmacology & Toxicology.

Ellen Rohde

Luke is a senior manager of IT operations at Verve, with 9 years of experience in IT Operations. Prior to joining Verve, he was a senior manager of IT operations and services at CRISPR Therapeutics. Prior to his IT career, he held a variety of jobs and positions; including four years, in the US military, as an intelligence analyst embedded with an Apache squadron and medium infantry brigade, and was honorably discharged, as a Sergeant. Following this experience, he went to culinary school, where he learned classic French cuisine, at the New England Culinary Institute in Essex VT. After moving to Boston to work at L’Espalier, he changed careers and moved into the IT field; most notably,  working for Dyax and CRISPR Tx.

Luke Spence

Emma Mei is a senior accountant at Verve Therapeutics, with over 4 years of experience in accounting. Prior to joining Verve, she worked as a senior auditor at a public accounting firm. She received her M.S in accounting from Suffolk University. She is a licensed CPA in the state of Massachusetts.

Emma Mei

Barry Ticho

Natalie Jordan is the associate director, program management at Verve Therapeutics. Prior to joining Verve, Natalie worked at Moderna, as a program manager on both research and clinical stage programs across multiple therapeutic areas. She has also previously held roles on the delivery sciences team, focused on lipid nanoparticle formulation development. Natalie received her B.S. in biomedical engineering from Boston University.

Natalie Jordan

Matthew Greenfield is the associate director, laboratory operations at Verve Therapeutics. Matt has over 20 years of experience in the pharmaceutical industry. Prior to working at Verve, Matt worked as a researcher for both EPIX and Ariad Pharmaceuticals contributing to the development of three approved medicines (Vasovist, Iclusig and Allunbrig). He most recently served as the associate director of lab operations at Alkermes. In addition to his position at Verve, Matt serves on the board of health in Middleton, Massachusetts. Matt received his B.S. in chemistry from the University of New Hampshire.

Matthew Greenfield

Greg Feinstein is a scientist, formulation at [Verve Therapeutics](/org/verve-therapeutics), with expertise in multiple varieties of nanoparticle systems. Prior to joining Verve, he worked primarily on developing an LNP system to deliver nucleic acids to the retina at [Generation Bio](/org/generation-bio).  He received both his BS and MS, in chemical engineering, from [Northeastern University](/org/northeastern-university).

Greg Feinstein

Abigail is a research associate, next generation sequencing at Verve Therapeutics. Abigail holds a Bachelor of Science, summa cum laude, in marine science, from the University of Maine, where she focused on the conservation of intertidal areas in Acadia National Park using umbrella species conservation practices. She is also a NOAA Hollings Scholar alumna, Fulbright Scholar, and Phi Beta Kappa member. Prior to joining Verve, Abigail worked in the eDNA (environmental DNA) Core Facility at the University of Maine where she gained experience with NGS workflow.

Abigail Muscat

Julia Chapman serves as Senior Vice President of Corporate Strategy and Planning at Verve.  Ms. Chapman is a biotech executive and advisor with a successful track record leading program, portfolio, and commercial strategy for novel therapeutic modalities. Through leadership roles at Novartis, Precision Biosciences, and BridgeBio, she has facilitated research and development of more than 20 therapies spanning vaccines, RNA medicines, cell and gene therapy, and gene-editing. Most recently, as Vice President of Business Development and Strategy at BridgeBio, she led development of AAV gene therapies for CNS, renal, and metabolic diseases, as well as partnerships to develop next-generation delivery technologies. Prior to Bridge, she led portfolio strategy and alliance management at Precision Biosciences where she supported successful Series B and IPO rounds, as well as development of partnerships with Gilead, Shire, and the University of Pennsylvania. Here, she developed in-depth knowledge of Familial Hypercholesterolemia and atherosclerotic cardiovascular disease as Precision’s portfolio included in vivo liver gene editing of PCSK9 and ANGPTL3 using meganuclease technology.  Julia spent her early career at Novartis in various roles of increasing responsibility within the TechOps, Development, and Commercial Organizations and in multiple geographies, including the UK, Germany, Italy, and Switzerland.  During her tenure at Novartis, her projects included Global Pandemic Planning, late-stage development of adjuvanted and quadrivalent vaccines, early-stage development of the SAM vaccine, and cross-functional M&A workstreams to support transactions with GSK and CSL.  She holds a B.S.E. in Biomedical Engineering and an MBA from Duke University.

Julia Chapman

Manini Mantri

Christopher Manoogian

Andrew Bellinger is the Chief Scientific Officer & Chief Medical Officer at [Verve Therapeutics](/org/verve-therapeutics). Andrew has also Co-Founded Lyndra where they led R&D. Andrew Bellinger has also been a Research Affiliate, Langer Lab at MIT, a Chief Medical Advisor at BetterFit Technologies, an Attending Cardiologist at Brigham and Women's Hospital, a Fellow in Cardiovascular Medicine, and a Clinical Fellow in Medicine, all while being a Resident Physician at UCSF Medical Center.

Andrew Bellinger completed their undergraduate studies at [Princeton University](/org/princeton), where they earned an A.B. in physics. Andrew then pursued a Master of Science in applied mathematics at [New York University](/org/nyu). After completing their MS, they enrolled at [Columbia University](/org/columbia-university) to earn their Doctor of Medicine (MD) through the Vagelos College of Physicians and Surgeons. Andrew also earned a Doctor of Philosophy (PhD) in biochemistry, biophysics, and molecular biology from [Columbia University](/org/columbia-university).

Sara Garcia - Associate Principal Scientist, Computational Biology, Ivan Ivanov - Scientist II, Editor Development, and Sagar Mudshinge - Scientist, Discovery Chemistry report to Andrew Bellinger. They are on a team with Seka Lazare - Associate Director, Next Generation Sequencing, Jeffrey Meltzer - VP, Quality, and Victoria Bartlett - VP, Program & Alliance Management. Andrew Bellinger reports to Sekar Kathiresan, Co-Founder & CEO.

Andrew Bellinger

Jessica Diaz is an account, payable associate, at Verve Therapeutics. She has over 6 years of experience working in accounting, and 5 years in accounts payable within the biotech industry. Prior to Verve, Ms. Diaz held positions with Kymera Therapeutics and Flexion Therapeutics. She received her B.A., in business administration, from Salem State University.

Jessica Diaz

Marina is a CMC senior project manager at Verve Therapeutics. Prior to joining Verve, Marina was a CMC project manager for Takeda Pharmaceutical’s global manufacturing sciences small molecule division, where she supported products and programs all over the world. Marina has over 10 years of diverse career experience, spending time in the plastics, coffee, and bioprocessing industries prior to pharma. She has a Bachelor of Science in chemical engineering with a focus in material science from Worcester Polytechnic Institute.

Marina Varlamova

Maryam is the director, of discovery chemistry at Verve Therapeutics. She is a nucleic acid chemist. She finished her studies at McGill University, in Montreal, before moving to California to pursue her postdoctoral studies at Stanford University. Soon after, she joined the industry and worked in different areas of nucleic acids discovery, from DNA data storage to mRNA therapeutics.

Maryam Habibian

J. Keith Joung

Kieran Avery is a Procurement Analyst at [Verve Therapeutics](/org/verve-therapeutics). Kieran has a bachelor's degree in biochemistry from [Brandeis University](/org/brandeis-university). Kieran has worked as a Research Technician at The Research Foundation for SUNY, an Access Services Assistant and an Undergraduate Laboratory Assistant at [Brandeis University](/org/brandeis-university), and a Subject Matter Expert at Impono LLC. Kieran interned as a Procurement MBA Intern at [Foundation Medicine](/org/foundation-medicine) from June 2020 to June 2021. Kieran was also a Graduate Research Assistant at the D'Amore-McKim School of Business at [Northeastern University](/org/northeastern-university) from September 2020 to October 2020.

Kieran Avery has a Master of Business Administration - MBA from D'Amore-McKim School of Business at [Northeastern University](/org/northeastern-university) with a focus in Healthcare Management, Supply Chain & Operations Management. They also have a Bachelor of Science (B.S.) in Neuroscience from [Brandeis University](/org/brandeis-university). Furthermore, they have various certifications from [LinkedIn](/org/linkedin) in topics such as Using Questions to Foster Critical Thinking and Curiosity, A Design Thinking Approach to Putting the Customer First, Business Process Improvement, and Dealing with the Seven Deadly Wastes.

Their manager is Ryan Stoeckel, Associate Director, Procurement.

Verve Therapeutics

Org chart

Teams

Leadership Team

Board of Directors

CEO and Executive Team

Founding Team

Discover similar companies